PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Summary

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Timeline

Start

2022-03-03

Primary completion

2025-05-21

Completion

2025-05-21

Outcome

Outcome not reported

Stopped: “The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).”

Drugs

Indications